Newswire (Published: Tuesday, May 23, 2017, Received: Thursday, May 18, 2017, 3:36:41 PM CDT)
Word Count: 525
New Prostate Cancer Study Findings Have Been Reported by Researchers at Washington University (Determination of the Role of Negative Magnetic Resonance Imaging of the Prostate in Clinical Practice: Is Biopsy Still Necessary?)
By a News Reporter-Staff News Editor at Cancer Weekly -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news originating from St. Louis, Missouri, by NewsRx correspondents, research stated, "To assess the negative predictive value (NPV) of multiparametric magnetic resonance imaging (mpMRI) for detection of prostate cancer (PCa) in routine clinical practice and to identify characteristics of patients for whom mpMRI fails to detect high-grade (Gleason score >= 7) disease. We reviewed our prospectively maintained database of consecutive men who received prostate mpMRI at our institution, interpreted by a clinical practice of academic radiologists."
Our news journalists obtained a quote from the research from Washington University, "Between January 2012 and December 2015, 84 men without any magnetic resonance imaging suspicious regions according to prior institutional classification, or with Prostate Imaging Reporting and Data System (PI-RADS) 1-2 lesions according to the PI-RADS system, underwent standard template transrectal ultrasound (TRUS)-guided prostate biopsy. Using these biopsy results, we calculated the NPV of mpMRI for the detection of PCa and identified patient risk factors for having a Gleason score >= 7 PCa on biopsy. High-grade PCa (Gleason score >= 7) was found on TRUS biopsy in 10.3% of biopsy-naive patients (NPV= 89.7%), 16.7% of patients with previous negative biopsy (NPV= 83.3%), and 13.3% of patients on active surveillance (NPV= 86.6%). On multivariate analysis, the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) estimated risk for high-grade PCa (as a continuous variable) was a significant predictor for high-grade PCa on biopsy (odds ratio 1.01, P<.01). Men with negative mpMRIs interpreted in a routine clinical setting have a significant risk of harboring Gleason score >= 7 PCa on a standard 12-region template biopsy, independent of indication."
According to the news editors, the research concluded: "Standard template TRUS prostate biopsy should still be recommended for patients with negative mpMRI, particularly those with elevated PCPTRC estimated risk of high-grade PCa."
For more information on this research see: Determination of the Role of Negative Magnetic Resonance Imaging of the Prostate in Clinical Practice: Is Biopsy Still Necessary? Urology, 2017;102():190-195. Urology can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier - www.elsevier.com; Urology - www.journals.elsevier.com/urology/)
The news correspondents report that additional information may be obtained from R.S. Wang, Washington University, Sch Med, Dept. of Radiol, St Louis, MO 63110, United States. Additional authors for this research include E.H. Kim, J.M. Vetter, K.J. Fowler, A.S. Shetty, A.J. Mintz, N.G. Badhiwala, R.L. Grubb and G.L. Andriole (see also Oncology - Prostate Cancer).
Keywords for this news article include: St. Louis, Missouri, United States, North and Central America, Magnetic Resonance, Epidemiology, Metastatic Prostate Cancer, Risk and Prevention, Oncology, Washington University.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
Education and Instruction
Saint Louis County
New York City
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices